-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – WMS-1 in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - WMS-1 in Head And Neck Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.WMS-1 in Head And Neck Cancer Drug Details:WMS-1 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMM-124E in Traveler’s Diarrhea
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMM-124E in Traveler's Diarrhea report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMM-124E in Traveler's Diarrhea Drug Details: IMM-124E is under development for the...
-
Product Insights
Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections – Drugs In Development, 2022, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape. Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus...
-
Product Insights
Diarrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels, and incontinence. Treatment includes medication and a healthy lifestyle. The Diarrhea Drugs in Development market research report provides an overview of the diarrhea pipeline landscape. The report provides comprehensive information on the therapeutics...
-
Product Insights
Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colitis is swelling (inflammation) of the large intestine (colon). It can have many different causes, including infections including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders, lack of blood flow, or past radiation to the large bowel. Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea, and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. The Colitis Drugs in Development market research report provides an overview of the colitis pipeline landscape....
-
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort. The NAFLD drugs in development market research report provides comprehensive information on the therapeutics under development for the NAFLD, complete...
-
Product Insights
Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome. The NASH drugs in development market research report provides comprehensive information on the...
-
Product Insights
Autism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Autism, also known as a complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication, and repetitive behaviors. Risk factors include the child’s sex, family history, fragile X syndrome, Tourette syndrome, and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives. The Autism drugs in development market research report provides comprehensive information on the therapeutics under development for Autism, complete with analysis by stage of development, drug target, mechanism of action (MoA),...
-
Product Insights
Colitis Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Colitis Global Clinical Trials Review, H1, 2017" provides an overview of Colitis clinical trials scenario. This report provides top line data relating to the clinical trials on Colitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...